Effects exerted by mesenchymal stem cells on monocytes obtained from patients with rheumatoid arthritis and progressive systemic sclerosis


esenchymal stem cells, rheumatoid arthritis, antigen presentation.

How to Cite

Vasilev, G., Krasimirova, E., Ivanova, M., Ivanova-Todorova, E., Tumangelova-Yuzeir, K., Gancheva, R., Stoilov, R. and Kyurkchiev, D. 2019. Effects exerted by mesenchymal stem cells on monocytes obtained from patients with rheumatoid arthritis and progressive systemic sclerosis. Revmatologiia (Bulgaria). 27, 3 (Oct. 2019), 44-54. DOI:https://doi.org/10.35465/27.3.2019.pp44-54.


In the context of autoimmune inflammatory diseases, the therapeutic benefits of mesenchymal stem cells (MSCs) could be found in their potential to exert immunosuppressive effects and to regulate the immune response. In pursuit of having a more complete look a the regulatory mechanisms  performed by AT-MSC, we examined the influence of adipose stem cells (AT-MSC) on blood monocytes from patients with rheumatoid arthritis (RA). Comparison of the effect exerted by the soluble factors produced by AT-MSC vs. cell culture control media, on peripheral blood mononuclear cells (PBMC), showed a significant decrease in the percentage of HLA-DR expressing monocytes, 55.3% (IQR 30-65%) vs. 72% (IQR 62-81%), p = 0.001, as well as a significant decrease in mean fluorescence intensity MFI of HLA-DR was observed, 265 MFI (IQR 102-896 MFI) vs. 473 MFI IQR 160-2201 MFI), p = 0.001. The percentage of CD14 expressing monocytes and CD14 MFI, was increased in PBMC cultured with AT-MSC conditioned media as opposed to control media: 11.7% (IQR 7.6-16.5%) vs. 6.6% (IQR 4.6-11.8%), p = 0.013 and the surface expression density of CD14, 2702 (IQR 1548-3418) vs. 1540 (IQR 1146-2140), p = 0.05. sVEGF-A levels in PBMC cultures from PA patients cultured with conditioned media from AT-MSC were significantly higher than PBMC cultured with control media suppressing secretion of sVEGF-A, 5012 (IQR 2516-5054 pg/ml) vs. 561 pg/ml (IQR 288-699 pg/ml), p = 0.001.




  1. Hoff mann A, Floerkemeier T, Melzer C, Hass R. Comparison of in vitro-cultivation of human mesenchymal stroma/stem cells derived from bone marrow and umbilical cord. J Tissue Eng Regen M 2016;1(9):2565-2581.
  2. Pittenger M. Multilineage Potential of Adult Human Mesenchymal Stem Cells. Science 1999; 284(5411):143-147.
  3. Nombela-Arrieta C, Ritz J, Silberstein L. The elusive nature and function of mesenchymal stem cells. Nat Rev Mol Cell Bio 2011;12(2):126-131.
  4. Álvaro-Gracia J, Jover J, García-Vicuña R et al. Intravenous administration of expanded allogeneic adipose-derived mesenchymal stem cells in refractory rheumatoid arthritis (Cx611): results of a multicentre, dose escalation, randomised, single-blind, placebo-controlled phase Ib/IIa clinical trial. Ann Rheum Dis 2016;76(1):196-202.
  5. Sun L, Akiyama K, Zhang H et al. Mesenchymal Stem Cell Transplantation Reverses Multiorgan Dysfunction in Systemic Lupus Erythematosus Mice and Humans. Stem Cells 2009;27(6):1421-1432.
  6. Yagi H, Soto-Gutierrez A, Parekkadan B et al. Mesenchymal Stem Cells: Mechanisms of Immunomodulation and Homing. Cell Transplant 2010; 19(6-7):667-679
  7. Nauta A, Fibbe W. Immunomodulatory properties of mesenchymal stromal cells. Blood 2007; 110(10):3499-3506.
  8. Vasilev G, Ivanova M, Ivanova-Todorova E et al. Secretory factors produced by adipose mesenchymal stem cells downregulate Th17 and increase Treg cells in peripheral blood mononuclear cells from rheumatoid arthritis patients. Rheumatol Int 2019;39(5):819-826.
  9. Ivanova-Todorova E, Bochev I, Mourdjeva M et al. Adipose tissue-derived mesenchymal stem cells are more potent suppressors of dendritic cells diff erentiation compared to bone marrow-derived mesenchymal stem cells. Immunol Lett 2009;126(1-2):37-42.
  10. Cohen J. Statistical Power Analysis. Curr Dir Psychol Sci 1992;1(3):98-101.
  11. Shi M, Liu Z, Wang F. Immunomodulatory properties and therapeutic application of mesenchymal stem cells. Clin Exp Immunol 2011;164(1):1-8.
  12. Monneret G. Mesenchymal stem cells: another anti-infl ammatory treatment for sepsis? Nat Med 2009;15(6):601-602.
  13. Rasmusson I. Immune modulation by mesenchymal stem cells. Exp Cell Res 2006;312(12): 2169-2179.
  14. Corthay A. A Three-cell Model for Activation of Naïve T Helper Cells. Scand J Immunol 2006;64(2):93-96.
  15. Curtsinger J, Mescher M. Infl ammatory cytokines as a third signal for T cell activation. Curr Opin Immunol 2010;22(3):333-340.
  16. Jakubzick C, Randolph G, Henson P. Monocyte diff erentiation and antigen-presenting functions. Nat Rev Immunol 2017;17(6):349-362.
  17. Xing Z, Gauldie J, Cox G et al. IL-6 is an antiinfl ammatory cytokine required for controlling local or systemic acute infl ammatory responses. J Clin Invest 1998;101(2):311-320.
  18. Maggini J, Mirkin G, Bognanni I et al. Mouse Bone Marrow- Derived Mesenchymal Stromal Cells Turn Activated Macrophages into a Regulatory-Like Profi le. PLoS One 2010;5(2):e9252.
  19. Harmey J, Bouchier-Hayes D. Vascular endothelial growth factor (VEGF), a survival factor for tumour cells: Implications for anti-angiogenic therapy. BioEssays 2002;24(3):280-283.
  20. Vacca P, Montaldo E, Vitale C et al. MSC and innate immune cell interactions: A lesson from human decidua. Immunol Lett 2015;168(2):170-174.
  21. Madrigal M, Rao K, Riordan N. A review of therapeutic effects of mesenchymal stem cell secretions and induction of secretory modifi cation by diff erent culture methods. J Transl Med 2014;12:260.
  22. Adorini L, Penna G, Giarratana N, Uskokovic M. Tolerogenic dendritic cells induced by vitamin D receptor ligands enhance regulatory T cells inhibiting allograft rejection and autoimmune diseases. J Cell Biochem 2002;88(2):227-233.
  23. Voron T, Colussi O, Marcheteau E et al. VEGF-A modulates expression of inhibitory checkpoints on CD8+T cells in tumors. J Exp Med 2015;212(2):139-148.
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.